| Literature DB >> 31665947 |
James B Adams1, Thomas J Borody2, Dae-Wook Kang3, Alexander Khoruts4, Rosa Krajmalnik-Brown5, Michael J Sadowsky6.
Abstract
Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (MTT), a type of intensive intestinal microbiota transplantation (IMT), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews IMT, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive MTT for autism.Expert opinion: An open-label study and a two-year follow-up suggest that MTT is relatively safe and effective in significantly reducing gastrointestinal disorders and autism symptoms, changing the gut microbiome structure, and increasing gut microbial diversity. Further research with larger, randomized, double-blind, placebo-controlled studies is warranted.Entities:
Keywords: Autism; constipation; diarrhea; fecal microbiota transplant; gastrointestinal symptoms; intestinal microbiota transplant; microbiota transplant therapy; vancomycin
Mesh:
Year: 2019 PMID: 31665947 DOI: 10.1080/17474124.2019.1687293
Source DB: PubMed Journal: Expert Rev Gastroenterol Hepatol ISSN: 1747-4124 Impact factor: 3.869